



# Marksans Pharma Ltd.

Date: 30<sup>th</sup> May, 2018

**BSE Limited**

Corporate Relation Department  
Phiroze Jeejeeboi Towers,  
Dalal Street,  
Mumbai – 400001.  
Scrip Code: 524404

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400051.  
Symbol: MARKSANS

**Sub: Audited Annual Financial Results for the financial year ended 31<sup>st</sup> March, 2018 and Auditors Report thereon.**

Dear Sir,

In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Audited Annual Financial Results for the financial year ended 31<sup>st</sup> March, 2018 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today i.e. 30<sup>th</sup> May, 2018 along with Auditors Report thereon.

The meeting commenced at 11:00 a.m. and concluded at 12:45 p.m.

In this connection, we hereby certify that the Auditors have given their reports on the Audited Annual Financial Results for the financial year ended 31<sup>st</sup> March, 2018 (both Standalone and Consolidated) with unmodified opinion.

You are requested to note the above in your records.

Thanking you.

Yours faithfully,

For **Marksans Pharma Limited**

**Harshavardhan Panigrahi**  
Company Secretary & Manager – Legal



**Auditor's Report on Standalone Financial Results of Marksans Pharma Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors of MARKSANS PHARMA LIMITED**

1. We have audited the accompanying Annual Standalone Financial Results ("the Financial Statement") of **MARKSANS PHARMA LIMITED** ("the Company") for the Year ended 31<sup>st</sup> March, 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This Financial Statement, which is the responsibility of the Company's management has been prepared in accordance with recognition and measurement principles laid down in Ind AS as notified under the Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express an opinion on this Financial Statement based on our audit.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatements. An Audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An Audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, this Financial Statement:
  - (i) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
  - (ii) Give a true and fair view of the Standalone Net Profit and other financial information for the year ended 31<sup>st</sup> March, 2018.

For V. S. Lalpuria & Co.  
Chartered Accountants

V. S. Lalpuria  
Proprietor  
Membership No. 015926  
Place : Mumbai  
Date : 30<sup>th</sup> May, 2018






**Auditor's Report on Annual Consolidated Financial Results of Marksans Pharma Limited  
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015**

**To the Board of Directors of MARKSANS PHAMA LIMITED**

1. We have audited the Annual Consolidated Financial Results ("the Financial Statement") of **MARKSANS PHARMA LIMITED** ("the Company") for the year ended 31<sup>st</sup> March, 2018, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Financial Statement, which is the responsibility of the Company's management, has been prepared in accordance with recognition and measurement principles laid down in Ind AS as notified under the Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express an opinion on this Financial Statement based on our audit.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Financial Statement is free of material misstatements. An Audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An Audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis for our opinion.
3. We did not audit the financial statements of 3 (three) subsidiaries included in the consolidated financial results incorporated outside India, whose consolidated financial statements reflect total assets (before intra-group eliminations) of Rs. 5686.13 Millions as at 31<sup>st</sup> March, 2018; as well as the total revenue (before intra-group eliminations) of Rs. 7605.49 Millions for the year ended 31 March 2018. These financial statements and other financial information have been audited by other Auditors whose reports have been furnished to us, and our opinion on the consolidated financial results for the year ended 31 March 2018, to the extent they have been derived from such financial statements is based solely on the report of such other Auditors.
4. In our opinion and to the best of our information and according to the explanations given to us and upon consideration of report of the auditors referred in paragraph 3 above, the Financial Statement:
  - (i) includes the results of the entities listed in Note 3 to the Financial Statement;
  - (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
  - (iii) give a true and fair view of the Consolidated Net Profit and other financial information for the year ended 31<sup>st</sup> March, 2018.

**For V. S. Lalpuria & Co.**  
**Chartered Accountants**

  
**V. S. Lalpuria**  
**Proprietor**  
**Membership No. 015926**



**Place : Mumbai**  
**Date : 30<sup>th</sup> May, 2018**

**MARKSANS PHARMA LIMITED**

Registered Office: 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri [West], Mumbai-400053 [CIN: L24110MH1992PLC066364]

Telephone No.: 022-4001 2000, Fax No.: 022-4001 2011, E-mail: info@marksanspharma.com

**AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2018**

(₹ in Million)

Sr. No.	PARTICULARS	STANDALONE					CONSOLIDATED	
		3 MONTHS ENDED			YEAR ENDED		YEAR ENDED	
		31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017	31.03.2018	31.03.2017
		(AUDITED)	(UNAUDITED)	(AUDITED)	(AUDITED)	(AUDITED)	(AUDITED)	(AUDITED)
1	Revenue from Operations	868.37	800.25	539.50	2,946.62	2,158.40	9,126.92	7,671.61
2	Other Income	0.79	-	2.62	1.22	69.51	3.55	70.22
3	<b>Total Income</b>	<b>869.16</b>	<b>800.25</b>	<b>542.12</b>	<b>2,947.84</b>	<b>2,227.91</b>	<b>9,130.47</b>	<b>7,741.83</b>
4	Expenses							
	Cost of Material Consumed	462.33	420.27	248.62	1,547.43	1,008.80	3,486.63	3,655.31
	Purchase of Stock - in- trade	51.79	55.87	33.20	183.26	108.19	1,539.18	1,411.50
	Changes in inventories of finished goods, work-in-process and stock-in-trade	(24.61)	(11.08)	3.07	(37.21)	6.74	205.46	(479.36)
	Employee benefits expense	111.40	116.61	102.52	458.56	397.71	1,477.48	1,496.98
	Finance cost	25.88	12.56	21.28	76.68	44.90	102.17	67.75
	Depreciation and amortisation expense	25.39	25.91	38.20	122.51	150.02	268.38	300.93
	Other expenses	160.08	103.52	144.59	430.09	392.07	1,553.19	1,139.74
	<b>Total Expenses</b>	<b>812.26</b>	<b>723.66</b>	<b>591.48</b>	<b>2,781.32</b>	<b>2,108.43</b>	<b>8,632.49</b>	<b>7,592.85</b>
5	<b>Profit/(Loss) before tax (3-4)</b>	<b>56.90</b>	<b>76.59</b>	<b>(49.36)</b>	<b>166.52</b>	<b>119.48</b>	<b>497.98</b>	<b>148.98</b>
6	<b>Tax expense:</b>							
	(1) Current Year	12.80	13.01	-	36.20	28.40	133.92	48.71
	(2) Earlier year	-	(0.00)	(19.59)	0.04	(31.37)	0.04	(31.37)
	(3) Deferred tax	0.78	7.39	(5.35)	6.02	6.99	6.02	18.29
	<b>Total Tax Expenses</b>	<b>13.58</b>	<b>20.40</b>	<b>(24.94)</b>	<b>42.26</b>	<b>4.02</b>	<b>139.98</b>	<b>35.63</b>
7	<b>Profit/(Loss) for the period (5-6)</b>	<b>43.32</b>	<b>56.19</b>	<b>(24.42)</b>	<b>124.26</b>	<b>115.46</b>	<b>358.00</b>	<b>113.35</b>
	<b>Other Comprehensive Income/(Loss)</b>							
	Items that will not be reclassified to Profit or Loss	1.95		(0.15)	1.95	(0.15)	1.95	(0.15)
	Income tax relating to above Items that will not be reclassified to Profit or Loss	(0.73)		0.05	(0.73)	0.05	(0.73)	0.05
	Items that will be reclassified to profit or loss						68.33	(32.31)
	Income tax relating to above Items that will be reclassified to Profit or Loss							
8	<b>Other Comprehensive Income/(Loss)</b>	<b>1.22</b>	<b>-</b>	<b>(0.10)</b>	<b>1.22</b>	<b>(0.10)</b>	<b>69.55</b>	<b>(32.41)</b>
9	<b>Total Comprehensive Income for the period</b>	<b>44.54</b>	<b>56.19</b>	<b>(24.52)</b>	<b>125.48</b>	<b>115.36</b>	<b>427.55</b>	<b>80.94</b>
10	Total Comprehensive Income attributable to:-							
	Non-Controlling interests	-	-	-	-	-	28.61	24.96
	Owners of the Company	<b>44.54</b>	<b>56.19</b>	<b>(24.52)</b>	<b>125.48</b>	<b>115.36</b>	<b>398.94</b>	<b>55.98</b>
11	Paid up Equity Share Capital (Face Value ₹1 each)	409.31	409.31	409.31	409.31	409.31	409.31	409.31
12	Earnings Per Share of ₹1 each							
	Basic	0.11	0.14	(0.06)	0.30	0.28	0.80	0.22
	Diluted	0.11	0.14	(0.06)	0.30	0.28	0.80	0.22



## ANNEXURE

## STATEMENT OF ASSETS AND LIABILITIES

(₹ in Million)

Statement of Financial Position	Standalone as at		Consolidated as at	
	31.03.2018	31.03.2017	31.03.2018	31.03.2017
	AUDITED	AUDITED	AUDITED	AUDITED
<b>ASSETS</b>				
<b>Non-current assets</b>				
Property, plant and equipment	878.81	918.97	1,863.68	1,645.02
Capital work-in-progress	-	3.60	-	3.60
Intangible assets	0.09	20.21	930.09	1,024.73
Intangible assets under development	-	-	-	-
<b>Financial assets</b>	-	-	-	-
(i) Investments	2,360.74	2,342.93	-	-
(ii) Loans	-	-	-	-
(iii) Other non-current financial assets	8.17	5.88	8.17	5.88
Deferred tax assets (net)	-	-	-	-
Other non-current assets	-	-	-	-
<b>Total non-current assets</b>	<b>3,247.81</b>	<b>3,291.59</b>	<b>2,801.94</b>	<b>2,679.23</b>
<b>Current assets</b>				
Inventories	422.93	292.43	2,181.24	1,900.87
<b>Financial Assets</b>	-	-	-	-
(i) Trade receivables	1,688.72	1,547.98	1,769.05	2,475.81
(ii) Cash and cash equivalents	7.14	25.62	398.77	251.62
(iii) Other Financial Assets	0.50	0.90	0.50	0.90
Other current assets	189.92	299.18	139.95	209.63
<b>Total current assets</b>	<b>2,309.21</b>	<b>2,166.11</b>	<b>4,489.51</b>	<b>4,838.83</b>
<b>TOTAL ASSETS</b>	<b>5,557.02</b>	<b>5,457.70</b>	<b>7,291.45</b>	<b>7,518.06</b>
<b>EQUITY AND LIABILITIES</b>				
<b>EQUITY</b>				
Equity share capital	409.31	409.31	409.31	409.31
Other Equity	-	-	-	-
Reserves and Surplus	3,880.40	3,779.53	4,299.33	3,925.02
Equity attributable to owners the Company	-	-	-	-
Non-Controlling Interest	-	-	95.50	62.47
<b>Total equity</b>	<b>4,289.71</b>	<b>4,188.84</b>	<b>4,804.14</b>	<b>4,396.80</b>
<b>LIABILITIES</b>				
<b>Non-current liabilities</b>				
<b>Financial liabilities</b>	-	-	-	-
(i) Borrowings	-	-	-	-
(ii) Other financial liabilities	100.00	110.00	100.00	110.00
Deferred tax liabilities (Net)	60.11	53.37	45.57	41.07
Other non-current liabilities	10.81	9.61	10.80	9.61
<b>Total non current liabilities</b>	<b>170.92</b>	<b>172.98</b>	<b>156.37</b>	<b>160.68</b>
<b>Current liabilities</b>				
<b>Financial liabilities</b>				
(i) Borrowings	663.09	732.29	1,174.13	1,097.10
(ii) Trade payables	233.33	206.03	674.81	1,617.84
(iii) Other financial liabilities	12.63	7.12	12.63	7.12
Other current liabilities	-	-	-	-
Provisions	166.83	119.32	378.94	207.40
Current tax liabilities (Net)	20.51	31.12	90.43	31.12
<b>Total current liabilities</b>	<b>1,096.40</b>	<b>1,095.88</b>	<b>2,330.94</b>	<b>2,960.58</b>
<b>Total liabilities</b>	<b>1,267.31</b>	<b>1,268.86</b>	<b>2,487.31</b>	<b>3,121.26</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>5,557.02</b>	<b>5,457.70</b>	<b>7,291.45</b>	<b>7,518.06</b>




**NOTES:**

- 1 The above AUDITED results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 30<sup>th</sup> May, 2018.
- 2 The board has recommended dividend of ₹ 0.05 (5%) per equity share of ₹ 1 each for the financial year 2017-18. The payment is subject to approval of the shareholders at the ensuing Annual General Meeting.
- 3 The Company has, for the first time, adopted Indian Accounting Standards ("Inds AS") from 1 April, 2017 and accordingly these results have been prepared in accordance with the Ind AS prescribed under Section 133 of the Companies Act 2013 read with the relevant rules issued there under and other Accounting pronouncements generally accepted in India. The format for unaudited quarterly financials results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015 dated 30 November, 2015 has been modified to comply with the requirements of SEBI's circular dated 05 July 2016, Ind AS and Schedule III ( Division II) to the Companies Act 2013 which are applicable to companies that are required to comply with Ind AS.
- 4 The reconciliation of Net Profit as previously reported (referred to as "Previous GAAP") and Ind AS is as under:

Particulars	(₹ in Million)		
	STANDALONE		CONSOLIDATED
	3 MONTHS ENDED 31.03.2017	12 MONTHS ENDED 31.03.2017	12 MONTHS ENDED 31.03.2017
Net Profit Under previous GAAP	5.69	122.25	95.18
Change in Fair value of Forward contract and currency exchange difference	(38.53)	(0.07)	(0.07)
Deferred tax adjustments and others	11.85	(0.47)	(0.47)
OCI-Remeasurement of the net defined benefit plans- Net of Tax	(0.10)	(0.10)	(0.10)
Other Ind AS adjustments	(3.44)	(6.25)	(6.25)
Exchange differences in translating the financial statements of a foreign operation			(32.31)
Net profit for the period under Ind AS	(24.52)	115.36	55.98

- 5 The reconciliation of Equity reported (referred to as "Previous GAAP") and Ind AS is as under:

Particulars	(₹ in Million)	
	STANDALONE	CONSOLIDATED
	Equity as at 31.03.2017	Equity as at 31.03.2017
(a) Share capital	519.31	519.31
(b) Reserves and surplus	3,781.03	3,926.51
<b>Total Equity as per previous Indian GAAP</b>	<b>4,300.34</b>	<b>4,445.82</b>
7% Redeemable Cumulative Preference shares of ₹100/- each	(110.00)	(110.00)
Proposed Dividend and tax thereon	33.90	33.90
Change in Fair value of Financial Assets and currency exchange difference	0.90	0.90
Deferred tax adjustments and others	(43.80)	(43.80)
OCI-Remeasurement of the net defined benefit plans- Net of Tax	(0.10)	(0.10)
Other Ind AS adjustments	7.60	7.60
<b>Total Equity As per Ind-AS (Except Non controlling Interest)</b>	<b>4,188.84</b>	<b>4,334.32</b>

- 6 The figures for the quarter ended 31st March, 2018 and 31st March 2017 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figure upto nine months of the relevant financial year.
- 7 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Marksans Pharma (U.K.) Limited, Marksans Pharma Inc. USA and Nova Pharmaceuticals Australasia Pty Ltd.
- 8 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 9 Statements of Assets and Liabilities is annexed hereto as an Annexure.
- 10 Previous period's/year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current period's figures.

Place: Mumbai.  
Date: 30th May, 2018  
[www.marksanspharma.com](http://www.marksanspharma.com)

For MARKSANS PHARMA LIMITED

MARK SALDANHA  
Managing Director

